ATE274496T1 - Pharmazeutische zusammensetzungen welche aryl- substituierte olefinische amin-verbindungen enthalten - Google Patents
Pharmazeutische zusammensetzungen welche aryl- substituierte olefinische amin-verbindungen enthaltenInfo
- Publication number
- ATE274496T1 ATE274496T1 AT98905108T AT98905108T ATE274496T1 AT E274496 T1 ATE274496 T1 AT E274496T1 AT 98905108 T AT98905108 T AT 98905108T AT 98905108 T AT98905108 T AT 98905108T AT E274496 T1 ATE274496 T1 AT E274496T1
- Authority
- AT
- Austria
- Prior art keywords
- alkyl
- amine
- buten
- methyl
- hydrogen
- Prior art date
Links
- -1 AMINE COMPOUNDS Chemical class 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 125000006527 (C1-C5) alkyl group Chemical group 0.000 abstract 6
- 229910052739 hydrogen Inorganic materials 0.000 abstract 5
- 125000001475 halogen functional group Chemical group 0.000 abstract 4
- 239000001257 hydrogen Substances 0.000 abstract 4
- 125000003118 aryl group Chemical group 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 2
- 150000002431 hydrogen Chemical class 0.000 abstract 2
- 125000006701 (C1-C7) alkyl group Chemical group 0.000 abstract 1
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 abstract 1
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 abstract 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- 208000018737 Parkinson disease Diseases 0.000 abstract 1
- 208000000323 Tourette Syndrome Diseases 0.000 abstract 1
- 208000016620 Tourette disease Diseases 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 abstract 1
- 208000015114 central nervous system disease Diseases 0.000 abstract 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
- 208000035231 inattentive type attention deficit hyperactivity disease Diseases 0.000 abstract 1
- 201000000980 schizophrenia Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/63—One oxygen atom
- C07D213/64—One oxygen atom attached in position 2 or 6
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/36—Radicals substituted by singly-bound nitrogen atoms
- C07D213/38—Radicals substituted by singly-bound nitrogen atoms having only hydrogen or hydrocarbon radicals attached to the substituent nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/61—Halogen atoms or nitro radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/26—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/30—Halogen atoms or nitro radicals
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/804,250 US6531606B1 (en) | 1997-02-21 | 1997-02-21 | Pharmaceutical compositions incorporating aryl substituted olefinic amine compounds |
| US08/804,248 US5861423A (en) | 1997-02-21 | 1997-02-21 | Pharmaceutical compositions incorporating aryl substituted olefinic amine compounds |
| PCT/US1998/003091 WO1998037071A1 (en) | 1997-02-21 | 1998-02-19 | Pharmaceutical compositions incorporating aryl substituted olefinic amine compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE274496T1 true ATE274496T1 (de) | 2004-09-15 |
Family
ID=27122682
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT98905108T ATE274496T1 (de) | 1997-02-21 | 1998-02-19 | Pharmazeutische zusammensetzungen welche aryl- substituierte olefinische amin-verbindungen enthalten |
Country Status (12)
| Country | Link |
|---|---|
| EP (1) | EP0973743B1 (de) |
| JP (1) | JP2001512486A (de) |
| KR (1) | KR100572189B1 (de) |
| AT (1) | ATE274496T1 (de) |
| AU (1) | AU749151B2 (de) |
| BR (1) | BR9807262A (de) |
| CA (1) | CA2281564A1 (de) |
| DE (1) | DE69825879T2 (de) |
| DK (1) | DK0973743T3 (de) |
| ES (1) | ES2226095T3 (de) |
| PT (1) | PT973743E (de) |
| WO (1) | WO1998037071A1 (de) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6979695B2 (en) | 1996-04-23 | 2005-12-27 | Targacept, Inc. | Compounds capable of activating cholinergic receptors |
| US20020052497A1 (en) | 2000-03-09 | 2002-05-02 | Targacept, Inc. | Compounds capable of activating cholinergic receptors |
| US6232316B1 (en) | 1998-06-16 | 2001-05-15 | Targacept, Inc. | Methods for treatment of CNS disorders |
| JP4240815B2 (ja) * | 1998-06-16 | 2009-03-18 | ターガセプト，インコーポレイテッド | アリール置換オレフィンアミンと、コリン受容体アゴニストとしてのアリール置換オレフィンアミンの使用 |
| US20050131034A1 (en) | 1998-06-16 | 2005-06-16 | Caldwell William S. | Compounds capable of activating cholinergic receptors |
| US7790757B2 (en) | 1998-06-16 | 2010-09-07 | Targacept, Inc. | Compounds capable of activating cholinergic receptors |
| EP1185514A1 (de) * | 1999-06-07 | 2002-03-13 | Targacept, Inc. | Pharmaceutische zusammensetzungen und verwendungsmethode |
| US20140150787A1 (en) * | 2012-12-04 | 2014-06-05 | Civitas Therapeutics, Inc. | Devices and methods for puncturing a capsule to release a powdered medicament therefrom |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9407447D0 (en) * | 1994-04-14 | 1994-06-08 | Glaxo Group Ltd | Chemical compounds |
| EP0801527B1 (de) * | 1995-01-06 | 2006-07-26 | Targacept, Inc. | Pharmazeutische zusammensetzungen zur vorbeugung und behandlung von störungen des zentralnervensystems |
| US5616707A (en) * | 1995-01-06 | 1997-04-01 | Crooks; Peter A. | Compounds which are useful for prevention and treatment of central nervous system disorders |
| US5616716A (en) * | 1996-01-06 | 1997-04-01 | Dull; Gary M. | (3-(5-ethoxypyridin)yl)-alkenyl 1 amine compounds |
-
1998
- 1998-02-19 CA CA002281564A patent/CA2281564A1/en not_active Abandoned
- 1998-02-19 WO PCT/US1998/003091 patent/WO1998037071A1/en not_active Ceased
- 1998-02-19 DK DK98905108T patent/DK0973743T3/da active
- 1998-02-19 KR KR1019997007590A patent/KR100572189B1/ko not_active Expired - Fee Related
- 1998-02-19 PT PT98905108T patent/PT973743E/pt unknown
- 1998-02-19 EP EP98905108A patent/EP0973743B1/de not_active Expired - Lifetime
- 1998-02-19 AT AT98905108T patent/ATE274496T1/de active
- 1998-02-19 JP JP53680798A patent/JP2001512486A/ja not_active Ceased
- 1998-02-19 BR BR9807262-5A patent/BR9807262A/pt not_active Application Discontinuation
- 1998-02-19 DE DE69825879T patent/DE69825879T2/de not_active Expired - Lifetime
- 1998-02-19 AU AU62806/98A patent/AU749151B2/en not_active Ceased
- 1998-02-19 ES ES98905108T patent/ES2226095T3/es not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| PT973743E (pt) | 2004-11-30 |
| DE69825879D1 (de) | 2004-09-30 |
| EP0973743B1 (de) | 2004-08-25 |
| DK0973743T3 (da) | 2004-11-29 |
| JP2001512486A (ja) | 2001-08-21 |
| AU749151B2 (en) | 2002-06-20 |
| KR100572189B1 (ko) | 2006-04-18 |
| EP0973743A1 (de) | 2000-01-26 |
| AU6280698A (en) | 1998-09-09 |
| KR20000075531A (ko) | 2000-12-15 |
| DE69825879T2 (de) | 2005-09-01 |
| WO1998037071A1 (en) | 1998-08-27 |
| ES2226095T3 (es) | 2005-03-16 |
| CA2281564A1 (en) | 1998-08-27 |
| BR9807262A (pt) | 2000-05-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MXPA04007470A (es) | Piridinonas sustituidas. | |
| IS1904B (is) | Hliðstæðar aðferðir við framleiðslu á nýjum (R)-5-karbamóýl-8-flúor-3-N,N-tvíútskiptum-amínó-3,4-díhýdró-2H-1-bensópýrönum | |
| UA66825C2 (uk) | Азаполіциклічні сполуки, конденсовані з арилом, фармацевтична композиція, спосіб лікування та спосіб зниження нікотинової залежності | |
| MY109737A (en) | Treatment and compounds. | |
| MXPA05009359A (es) | Tetrahidroisoquinolinas 2,5- y 2,6 substituidas para uso como moduladores 5-ht6. | |
| HUP0302167A2 (hu) | Metabotropikus glutamát receptor antagonista hatású kinolinszármazékok, a vegyületeket tartalmazó gyógyszerkészítmények és eljárás előállításukra | |
| BR9408450A (pt) | Antagonistas da neuroquinina diazabiciclicos | |
| ATE136030T1 (de) | Azaheterocyclylmethyl-chromane als wirkstoffe zur behandlung von erkrankungen des zentralnervensystems | |
| ATE427936T1 (de) | Substituierte piperidin-verbindungen als modulatoren der chemokine receptor aktivitat | |
| CA2406080A1 (en) | Antitumoral ecteinascidin derivatives | |
| MY120976A (en) | 2-amino-6-(2-substituted-4-phenoxy)- substituted- pyridines | |
| EA200100774A1 (ru) | Гетероциклические производные с функциональными группами (варианты), фармацевтическая композиция и комбинация, способ модулирования активности рецептора хемокина (варианты), способ профилактики инфицирования вич и лечения инфекции вич, замедления проявления спид и лечения спид, способ лечения воспалительных процессов | |
| SE9702564D0 (sv) | New compounds | |
| EA200601194A1 (ru) | Новые производные бензофурана, используемые для профилактики или лечения нарушений, связанных с 5-ht-рецептором | |
| NO20020282L (no) | Nytt difenyl-piperidinderivat | |
| WO2005066166A3 (en) | 3-quinuclidinyl amino-substituted biaryl derivatives | |
| DE69535131D1 (de) | Pharmazeutische zusammensetzungen zur vorbeugung und behandlung von störungen des zentralnervensystems | |
| ATE274496T1 (de) | Pharmazeutische zusammensetzungen welche aryl- substituierte olefinische amin-verbindungen enthalten | |
| DE60004671D1 (de) | Neue piperazinylalkylthiopyrimidine derivate, diese enthaltende pharmazeutische zusammenstellungen und verfahren zu deren herstellung | |
| SE9902551D0 (sv) | Novel compounds | |
| ATE214375T1 (de) | Piperazinylalkylthiopyrimidin derivate, diese enthaltende pharmazeutische zusammensetzungen und verfahren zu deren herstellung | |
| ATE229953T1 (de) | Naphtho-imidazo(1,2-a)pyridin derivate, deren herstellung und deren verwendung in der behandlung von störungen des zentralnervensystems | |
| UY28119A1 (es) | Nuevos derivados que contienen fosforo | |
| ES2119454T3 (es) | Derivados de pirrolidina para el tratamiento de los desordenes relacionados con la csk y la gastrina. | |
| UA81405C2 (en) | Substituted pyridinones as modulators of p38 map kinase |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 0973743 Country of ref document: EP |